Operationalizing 30-minute ECG review
Case Study

Addressing the unique post-marketing cardiac safety monitoring requirements of an autoimmune disease product.

Customer needs to respond to regulatory guidance issued on rigorous monitoring of cardiac safety by clinics six hours post-dose, with reporting requirements varying across geographies – because of the risk of transient bradycardias and heart block after the first dose, the FDA heightened the recommended level of cardiovascular monitoring of all patients after their first dose At the time, no clinical services provider had resources in place to facilitate expedited analysis. Learn how IQVIA has been able to accommodate a 30-minute ECG review turn around with high quality delivery since 2012.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.